The drugs being called out specifically in the lawsuit are Viread, Truvada, Atripla, Complera and Stribild — all of which contain TDF as an active ingredient.
According to Johnson and Rochester, Gilead was aware that the dose of TDF in its drugs posed a significant risk of toxic effects, and had accumulated substantial evidence indicating that TDF caused harm to patients' kidneys and bones by the time it developed Stribild. The two are requesting declaratory relief and monetary compensation for their damages.
This isn’t the first time Gilead has faced similar lawsuits regarding its HIV drugs. In 2018, two men accused the company of delaying the development of a new HIV drug that could have replaced drugs linked to TDF and kidney and bone problems. Another lawsuit in 2019 alleged that Gilead cut deals with several pharma companies to protect combo HIV treatments from generics competition.